Currently Viewing:
Evidence-Based Oncology July 2016
ASCO'S TAPUR Study Continues to Grow
Cate Douglass
Nivolumab Safe in Glioblastoma
Surabhi Dangi-Garimella, PhD
Currently Reading
Promising Results With Combination Immunotherapy in Solid Tumors and Leukemia
Surabhi Dangi-Garimella, PhD
Zeroing in on Predictive Biomarkers for Cancer Immunotherapy
Surabhi Dangi-Garimella, PhD
Lessons to Learn From the NICE Cancer Care Model
Surabhi Dangi-Garimella, PhD
Clinical Interpretation of the ASCO Recommendations on Quality and Value
Surabhi Dangi-Garimella, PhD
Aggressive Cancer Care Widely Used Among Patients at the End of Life
Cate Douglass
Understanding and Mitigating the Financial Burden of Cancer Patients
Surabhi Dangi-Garimella, PhD
ASCO Study Finds Daratumumab Could Be Economical Over Pomalidomide—Dexamethasone in MM
Surabhi Dangi-Garimella, PhD
The Value of a 21-Gene Test in Early-Stage Breast Cancer
Surabhi Dangi-Garimella, PhD
Cancer Drug Prices Follow a Sharp Upward Trajectory Post Launch
Surabhi Dangi-Garimella, PhD
Web App Boosts Survival for Lung Cancer Patients
Anita T. Shaffer
Cabozantinib Improves Survival in Renal Cell Carcinoma
Jason M. Broderick

Promising Results With Combination Immunotherapy in Solid Tumors and Leukemia

Surabhi Dangi-Garimella, PhD
As immunotherapy-particularly the checkpoint inhibitors-continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes.
As immunotherapy—particularly the checkpoint inhibitors—continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes. During a June 4, 2016, session during the annual meeting of the American Society of Clinical Oncology, in Chicago, the results from some of these trials were shared.

Some of the questions that were addressed during the session included: 
  • How do we use the growing number of next-generation checkpoint inhibitors? 
  • How do we use them in combination with vaccines, radiation, chemotherapy, and other modalities?
  • Do we need to investigate biomarkers other than the expression of programmed death ligand-1 (PD-L1)?
Combining Nivolumab and Ipilimumab in SCLC
Scott Joseph Antonia, MD, PhD, chair, Department of Thoracic Oncology Department and program leader of the Immunology Program, H. Lee Moffitt Cancer Center, discussed results of the CheckMate 032 trial, in which the programmed death-1 (PD-1) receptor inhibitor nivolumab was used alone or combined with ipilimumab in the treatment of recurrent small cell lung cancer (SCLC).1 
It has been over a year since nivolumab was approved in the United States for patients who have progressed on their existing treatment for metastatic non-small cell lung cancer (NSCLC)—however, nivolumab was rejected in the United Kingdom by the National Institute for Health and Care Excellence, or NICE, for patients with advanced NSCLC.2 Antonia said that there’s been trivial progress with SCLC, which he described as being a very stubborn disease. While majority of patients respond to frontline chemotherapy, a majority of them relapse, and then the response rates for the next line of treatment plummets, he explained. 
Antonia said that CheckMate 032 was designed to evaluate nivolumab, with or without ipilimumab, in advanced tumors including SCLC. Eligibility criteria for trial participation was advanced SCLC with progressive disease after 1 or more platinum-based chemotherapy, regardless of platinum sensitivity or tumor PD-L1 expression. The primary endpoint of the trial was objective response rate (ORR), with secondary endpoints of safety, overall survival (OS), progression-free survival (PFS), and biomarker expression. The 216 patients enrolled in the trial were divided into 3 cohorts: 
  • 98 patients were treated with nivolumab alone, at a dose of 3 mg/kg (N3) 
  • 61 patients were treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg (N1/I3)
  • 54 patients were treated with nivolumab 3 mg/kg and ipilimumab 1 mg/kg (N3/I1) 
Based on the data presented, a majority of the patients in each cohort expressed less than 1% PD-L1. Additionally, 59% of patients in the nivolumab-alone cohort, 48% in the N1/I3 cohort, and 58% in the N3/I1 cohort had received 2 or more prior lines of treatment.
Antonia showed toxicity data for the trial, saying that toxicity was greater in the combination arms. “Three treatment-related deaths were observed among the 114 patients treated with the combination therapy. However, patients were willing to remain on their treatment despite the toxicity,” he said. Response rates doubled with the combination therapy, including in platinum-resistant patients. Majority of the responders had a rapid, durable response, and response was independent of PD-L1 expression. Antonia said that PD-L1 negative patients responded just as well. Median OS, he showed, was 7.7 months for the N1/I3 cohort and 6 months for the N3/I1 cohort—significantly greater than the 4 months observed in patients treated with nivolumab alone.

Further, the 1-year OS rate was:
  • 33% in the single-drug arm
  • 43% in the N1/I3 arm
  • 35% in the N3/I1 arm
Antonia concluded that the survival rates from this early study are encouraging. The safety profile observed in the CheckMate 032 trial for SCLC was no different from that observed in other diseases treated with the combination, with higher rates of adverse events (AEs) compared with nivolumab alone. Dose expansion trials and studies in combination with other agents are ongoing, Antonia said, and include:
  • CheckMate 032 expansion study in 250 patients
  • CheckMate 331, nivolumab versus chemotherapy (topotecan or amrubicin) in patients with relapsed SCLC
  • CheckMate 451 nivolumab versus N1/I3 versus placebo in patients with extensive SCLC following platinum-based first-line
Based on the results of this study, nivolumab 1 mg/kg and ipilimumab 3 mg/kg was the dose of choice for a phase 3 study with this combination in SCLC patients. 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up